Legal & General Group Plc Has $404.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Legal & General Group Plc boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 887,780 shares of the biopharmaceutical company’s stock after acquiring an additional 15,009 shares during the period. Legal & General Group Plc owned approximately 0.67% of Alnylam Pharmaceuticals worth $404,828,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $27,000. Atlantic Union Bankshares Corp acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $30,000. Ameriflex Group Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth $32,000. Finally, ORG Partners LLC raised its stake in Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the firm’s stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president owned 24,848 shares in the company, valued at $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,923 shares of company stock valued at $18,072,087 over the last ninety days. 1.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on ALNY shares. Leerink Partners reduced their price objective on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Stifel Nicolaus raised their price target on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Bank of America reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Finally, Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $477.96.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $322.38 on Wednesday. The stock has a market capitalization of $42.75 billion, a PE ratio of 188.53 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company’s 50 day simple moving average is $349.24 and its two-hundred day simple moving average is $412.24. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.65) earnings per share. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.